IP Library Granted Patent US 10,927,178
Granted Patent B2
US 10,927,178 · App. 16/535,477 · Granted Feb 23, 2021

Anti-CXCR4 antibodies and antibody-drug conjugates

Inventors: Shu-Hui Liu (Redwood City, CA); Flavia Mercer Pernasetti (San Diego, CA); Wei-Hsien Ho (Belmont, CA)
Assignee: PFIZER INC.
C07K16/2866C12N5/10C12N15/09A61K39/3955A61K47/6803A61K47/6809A61K47/6847A61K47/6849A61K47/6851A61K49/0002A61K2039/505C07H21/04C07K14/7158C07K2317/24C07K2317/33C07K2317/56C07K2317/565C07K2317/73C07K2317/732C07K2317/734C07K2317/76C07K2317/92C12N2330/50C12N2510/02C12N2800/107
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,927,178
App. No.
16/535,477
Granted
Feb 23, 2021
Kind
B2
Abstract

The present invention provides antibodies and related molecules that bind to chemokine receptor 4 (CXCR4). The invention further provides antibody-drug conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and anti-CXCR4 antibody-drug conjugates for the treatment of a disorder associated with CXCR4 function or expression (e.g., cancer), such as colon, RCC, esophageal, gastric, head and neck, lung, ovarian, pancreatic cancer or hematological cancers.

Claims (5)

1. An isolated polynucleotide comprising a nucleotide sequence encoding an antibody, or an antigen binding fragment thereof, that binds to chemokine receptor 4 (CXCR4) and comprises:

a) a heavy chain variable (VH) CDR1 comprising the amino acid sequence shown in SEQ ID NO: 107, 108, 109, 113 or 114; a VH CDR2 comprising the amino acid sequence shown in SEQ ID NO: 110 or 111; and a VH CDR3 comprising the amino acid sequence shown in SEQ ID NO: 112; and;

b) a light chain variable region (VL) CDR1 comprising SEQ ID NO: 131; a VL CDR2 comprising 132; and a VL CDR3 comprising SEQ ID NO: 133.

2. A vector comprising the polynucleotide of claim 1 .

3. An isolated host cell that recombinantly produces the antibody or antigen binding fragment thereof of claim 1 .

Assignments (1)
ASSIGNEE ADDRESS CORRECTION Recorded Mar 20, 2023
From: PFIZER INC.
To: PFIZER INC.
Reel/Frame 063119/0087 →